U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H27N
Molecular Weight 293.4466
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUDIPINE

SMILES

CC(C)(C)N1CCC(CC1)(c2ccccc2)c3ccccc3

InChI

InChIKey=QIHLUZAFSSMXHQ-UHFFFAOYSA-N
InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3

HIDE SMILES / InChI
Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-B enzyme and stimulating aromatic L-amino acid decarboxylase. Also the drug inhibits the dopamine re-uptake and has weak affinity to NMDA and muscarinic receptors. Budipine passes the blood-brain barrier, is metabolized by hydroxylation, and is excreted by both in urine and feces within 24 h.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27338
Gene ID: 4129.0
Gene Symbol: MAOB
Target Organism: Homo sapiens (Human)
5.0 µM [IC50]
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
11.0 µM [IC50]
Target ID: P20711
Gene ID: 1644.0
Gene Symbol: DDC
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PARKINSAN

Approved Use

For combination therapy of Parkinson's disease.

Launch Date

8.5207679E11
PubMed

PubMed

TitleDatePubMed
[Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines].
1984
Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease.
2000 Sep
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
2001 Aug
Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings.
2001 May
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
2002 May
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
2003 May 26
Antiapoptotic effects of budipine.
2004 Oct
Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats.
2005 Jul
The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.
2005 Jul 22-29
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
2006 Jan
Paradoxical aspects of parkinsonian tremor.
2008 Jan 30
A new strategy for antidepressant prescription.
2010
Patents

Patents

Sample Use Guides

The dosage is determined individually. The treatment should start with 3 times daily 10 mg budipine hydrochloride. If necessary, the daily dose should be increased at the earliest after 1 week to 3 x 20 mg budipine hydrochloride or 2 x 30 mg budipine hydrochloride.
Route of Administration: Oral
In Vitro Use Guide
10(-7), 10(-8), 10(-9) mol/l of budipine significantly reduced release of TNF-alpha and Il-6 in PBMC and decreased apoptotic cell death after 50 hours and 74 hours in the SH-SY 5Y cells.
Name Type Language
BUDIPINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
1-TERT-BUTYL-4,4-DIPHENYLPIPERIDINE
Systematic Name English
BUDIPINE [MI]
Common Name English
BUDIPINE [WHO-DD]
Common Name English
BUDIPINE [INN]
Common Name English
BUDIPINE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C93038
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
WHO-VATC QN04BX03
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
WHO-ATC N04BX03
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
NCI_THESAURUS C38149
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
Code System Code Type Description
CAS
57982-78-2
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
MERCK INDEX
M2747
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY Merck Index
PUBCHEM
68778
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
EPA CompTox
57982-78-2
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
FDA UNII
L9026OPI2Z
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
NCI_THESAURUS
C73271
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
DRUG CENTRAL
420
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
RXCUI
19832
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
261-062-4
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
EVMPD
SUB05956MIG
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL334491
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
MESH
C026710
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
INN
4037
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY
DRUG BANK
DB13502
Created by admin on Sat Jun 26 05:00:29 UTC 2021 , Edited by admin on Sat Jun 26 05:00:29 UTC 2021
PRIMARY